Europe’s most valuable Biotech just launched 2 new Trials

13/07/2016 - 3 minutes

Within a week, Actelion has announced both Phase II and III trial studies for insomnia and hypertension in children. Even for Europe’s most valuable biotech, this is an impressive period.

Actelion Insomnia PAH Trials biotech logoActelion is to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia. The day before this, it also announced a Phase III trial with macitentan (Opsumit) in children with pulmonary arterial hypertension (PAH).

This is even more impressive when you consider that July is the beginning of the ‘low season’ for the Biotech and Pharma industries (and  most industries) as the Summer starts. Indeed, announcements in such close succession are usually only around the January boom, when conferences like the J.P. Morgan inspire companies to save their news for release all at once.

Nonetheless, Actelion is by far the most valuable biotech within Europe, with a net worth of around €17Bn. It’s a huge success story which started out very small,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member